M Ernst1, F Butscheid2, J Fiehler3, O Wittkugel4, K Alfke5, O Jansen6, D Petersen7, C Koch7, B Eckert8. 1. Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Haus Ost 22 (O 22), Martinistr. 52, 20246, Hamburg, Germany. m.ernst@uke.de. 2. Department of Neurology, Hospital Buchholz, Buchholz in der Nordheide, Germany. 3. Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Haus Ost 22 (O 22), Martinistr. 52, 20246, Hamburg, Germany. 4. Radiological Office Buchholz, Buchholz in der Nordheide, Germany. 5. Department of Neuroradiology, Helios Klinik Schwerin, Schwerin, Germany. 6. Department of Neuroradiology, University Medical Center Kiel, Kiel, Germany. 7. Department of Neuroradiology, University Medical Center Luebeck, Luebeck, Germany. 8. Department of Neuroradiology, Asklepios Klinik Altona, Hamburg, Germany.
Abstract
PURPOSE: The treatment mode in acute vertebrobasilar occlusion (VBO) remains uncertain. We analyzed efficacy and safety of intravenous glycoprotein IIb/IIIa inhibitor (IV GPI) plus subsequent intra-arterial thrombolysis with or without additional endovascular mechanical therapy (percutaneous transluminal angioplasty/stenting or thrombus aspiration) and sought treatment factors that predict good clinical outcome. METHODS: We retrospectively analyzed 120 cases of patients with angiographically proven acute VBO. Multivariate logistic regression was used to identify independent predictors for clinical outcome and included level of consciousness, age, sex, time to angiography, GPI agent, admission mode, occlusion type, recanalization success, and endovascular treatment mode. Clinical follow-up was dichotomized in no to moderate disability (modified Rankin scale (mRS) 0-3) vs. severe disability or death (mRS 4-6). RESULTS: Median National Institutes of Health stroke scale (NIHSS) score on admission was 32, and mean NIHSS score was 24. A total of 49 patients (41 %) developed no to moderate disability (mRS 0-3), and 39 patients (33 %) died. Thrombolysis in myocardial infarction 2/3 recanalization success was achieved in 97 patients (80.8 %). Symptomatic intracerebral hemorrhages occurred in 11 patients (9 %). Mild impairment of consciousness (p < 0.001) and embolic occlusion type (p = 0.01) were significant predictors of favorable outcome. Clinical outcome in recanalized patients was better, but not statistically significant (p = 0.055). CONCLUSIONS: Our results indicate that combined therapy with IV GPI and subsequent endovascular therapy may be a valid treatment strategy in acute VBO. With this treatment approach, a preserved vigilance before treatment and an embolic occlusion type are associated with no to moderate disability.
PURPOSE: The treatment mode in acute vertebrobasilar occlusion (VBO) remains uncertain. We analyzed efficacy and safety of intravenous glycoprotein IIb/IIIa inhibitor (IV GPI) plus subsequent intra-arterial thrombolysis with or without additional endovascular mechanical therapy (percutaneous transluminal angioplasty/stenting or thrombus aspiration) and sought treatment factors that predict good clinical outcome. METHODS: We retrospectively analyzed 120 cases of patients with angiographically proven acute VBO. Multivariate logistic regression was used to identify independent predictors for clinical outcome and included level of consciousness, age, sex, time to angiography, GPI agent, admission mode, occlusion type, recanalization success, and endovascular treatment mode. Clinical follow-up was dichotomized in no to moderate disability (modified Rankin scale (mRS) 0-3) vs. severe disability or death (mRS 4-6). RESULTS: Median National Institutes of Health stroke scale (NIHSS) score on admission was 32, and mean NIHSS score was 24. A total of 49 patients (41 %) developed no to moderate disability (mRS 0-3), and 39 patients (33 %) died. Thrombolysis in myocardial infarction 2/3 recanalization success was achieved in 97 patients (80.8 %). Symptomatic intracerebral hemorrhages occurred in 11 patients (9 %). Mild impairment of consciousness (p < 0.001) and embolic occlusion type (p = 0.01) were significant predictors of favorable outcome. Clinical outcome in recanalized patients was better, but not statistically significant (p = 0.055). CONCLUSIONS: Our results indicate that combined therapy with IV GPI and subsequent endovascular therapy may be a valid treatment strategy in acute VBO. With this treatment approach, a preserved vigilance before treatment and an embolic occlusion type are associated with no to moderate disability.
Authors: M Espinosa de Rueda; G Parrilla; J Zamarro; B García-Villalba; F Hernández; A Moreno Journal: AJNR Am J Neuroradiol Date: 2012-11-01 Impact factor: 3.825
Authors: Mario Siebler; Michael G Hennerici; Dietmar Schneider; Gerhard M von Reutern; Rüdiger J Seitz; Joachim Röther; Otto W Witte; Gerhard Hamann; Ulrich Junghans; Arno Villringer; Jochen B Fiebach Journal: Stroke Date: 2011-08-18 Impact factor: 7.914
Authors: Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni Journal: N Engl J Med Date: 2008-09-25 Impact factor: 91.245
Authors: M Arnold; K Nedeltchev; G Schroth; R W Baumgartner; L Remonda; T J Loher; F Stepper; M Sturzenegger; B Schuknecht; H P Mattle Journal: J Neurol Neurosurg Psychiatry Date: 2004-06 Impact factor: 10.154
Authors: Wouter J Schonewille; Christine A C Wijman; Patrik Michel; Christina M Rueckert; Christian Weimar; Heinrich P Mattle; Stefan T Engelter; David Tanne; Keith W Muir; Carlos A Molina; Vincent Thijs; Heinrich Audebert; Thomas Pfefferkorn; Kristina Szabo; Perttu J Lindsberg; Gabriel de Freitas; L Jaap Kappelle; Ale Algra Journal: Lancet Neurol Date: 2009-07-03 Impact factor: 44.182
Authors: Mervyn D I Vergouwen; Ale Algra; Thomas Pfefferkorn; Christian Weimar; Christina M Rueckert; Vincent Thijs; L Jaap Kappelle; Wouter J Schonewille Journal: Stroke Date: 2012-09-18 Impact factor: 7.914
Authors: Vicky Chalos; Rob A van de Graaf; Bob Roozenbeek; Adriaan C G M van Es; Heleen M den Hertog; Julie Staals; Lukas van Dijk; Sjoerd F M Jenniskens; Robert J van Oostenbrugge; Wim H van Zwam; Yvo B W E M Roos; Charles B L M Majoie; Hester F Lingsma; Aad van der Lugt; Diederik W J Dippel Journal: Trials Date: 2020-07-14 Impact factor: 2.279
Authors: Rob A van de Graaf; Vicky Chalos; Gregory J Del Zoppo; Aad van der Lugt; Diederik W J Dippel; Bob Roozenbeek Journal: Front Neurol Date: 2018-04-16 Impact factor: 4.003